Assessment of Drug–Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials

Background and Objective Taspoglutide, a glucagon-like peptide-1agonist, like native glucagon-like peptide-1, delays gastric emptying time and prolongs intestinal transit time, which may alter the pharmacokineticsof concomitantly administered oral drugs. The effect of taspoglutideon the pharmacokineticsof five oral drugs commonly used in patients with type 2 diabetes mellitus was assessed in healthy subjects.